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Abstract
Background This article addresses the choice of state structure
in a cost-effectiveness multi-state model. Key model outputs,
such as treatment recommendations and prioritisation of future
research, may be sensitive to state structure choice. For
example, it may be uncertain whether to consider similar dis-
ease severities or similar clinical events as the same state or as
separate states. Standard statistical methods for comparing
models require a common reference dataset but merging states
in a model aggregates the data, rendering these methods invalid.
Methods We propose a method that involves re-expressing a
model with merged states as a model on the larger state space in
which particular transition probabilities, costs and utilities are
constrained to be equal between states. This produces a model
that gives identical estimates of cost effectiveness to the model
with merged states, while leaving the data unchanged. The
comparison of state structures can be achieved by comparing
maximised likelihoods or information criteria between con-
strained and unconstrained models. We can thus test whether
the costs and/or health consequences for a patient in two states
are the same, and hence if the states can be merged. We note
that different structures can be used for rates, costs and utilities,
as appropriate.
Application We illustrate our method with applications to
two recent models evaluating the cost effectiveness of
prescribing anti-depressant medications by depression
severity and the cost effectiveness of diagnostic tests for
coronary artery disease.
Conclusions State structures in cost-effectiveness models
can be compared using standard methods to compare
constrained and unconstrained models.
Key Points for Decision Makers
State-transition cost-effectiveness models with different
state structures can give different recommendations on
treatment decisions or research prioritisation. To date,
there have been no formal statistical methods described
for comparing different state structures.
Merging two states in a transition model, such as similar
types of event, is practically equivalent to constraining
the outward transition probabilities, costs and utilities to
be equal for the two states. Thus, the state structures can
be compared by assessing whether these constraints are
reasonable. This can be done using standard methods for
comparing statistical models, and suitable data.
For example, comparing transition probabilities requires
data consisting of the numbers of patients observed to
transition out of the states of interest to each potential
destination. To compare costs and utilities between
states, individual-level samples are required. Maximum
likelihood and Akaike’s information criterion can then
be used to assess the constraints. If such data are not
available, they might be derived from published
summaries, or the comparison can be made informally.
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1 Introduction
Health economic evaluations rely on cost-effectiveness
models, such as Markov multi-state models [1], to produce
accurate comparative assessments of the costs and health
effects of different interventions for the management of
disease. Given a cost-effectiveness model, there may be
uncertainty about the correct transition probabilities, costs
or utilities. This is commonly termed parameter uncertainty
and managed by probabilistic sensitivity analysis [2, 3].
Research recommendations can also be guided by the
expected value of perfect information (EVPI) and expected
value of partial perfect information, comparing the benefits
in terms of costs and monetised health effects gained from
a decision based on evidence, where parameter uncertainty
is removed or reduced, with that based on current evidence
[4].
However, all models are idealised representations and
the choice of structure for the model may be uncertain.
Moreover, different choices can change decision recom-
mendations, as found in models for breast cancer and in
varicella vaccination [5, 6]. In this article, we consider
uncertainty about the choice of states in a state-transition
health economic model, a subject which has, to our
knowledge, not yet been formally addressed. An example
in coronary artery disease (CAD) is the choice between a
model with split and merged severities of CAD, illustrated
in Fig. 1. The split-state model divides the ‘CAD’ state into
‘high-risk CAD’ and ‘low-risk CAD’, as severity may have
an effect on costs, health utilities and the probability of
death. These structural choices are currently made infor-
mally, on the basis of clinical opinion and the availability
of data [7]. Guidelines recommend scenario analyses or
parameterising structural uncertainties [2, 8, 9], but it is
often unclear how they can be parameterised.
Formal statistical approaches for comparing model
structures against the data used to build them include the
Akaike information criterion (AIC) [10, 11] and, for
Bayesian models, the deviance information criterion
[12, 13]. These trade off the fit to the data, represented by
the likelihood, with the complexity, related to the effective
number of parameters, of the models. Thus, they can find
the optimal balance between the risk of bias (from
excluding important events or predictors) and the reduced
uncertainty in the estimates from a smaller model. These
criteria can also be used to construct weighted averages
over the possible structures [11, 14]. However, these
methods are only valid for models fit to the same datasets
and it has been shown that multi-state models with dif-
ferent state structures use different datasets [15]. Another
approach is to split the model into a series of sub-functions
and add discrepancy parameters to the outputs of these
functions to represent state structure uncertainty [16].
However, the discrepancies do not indicate which
assumptions are more plausible and can be difficult to
interpret for complex models. A further approach is to
compare the ability of the models to predict the events
represented by both models [15, 17], in the above CAD
example, this would be CAD and death. However, calcu-
lating the appropriate measure of fit for the restricted
information criteria described in this article is technically
demanding. State structures might also be compared by
informal validation against external data if available.
We propose a method that allows the choice between
state structures to be parameterised, and for which standard
likelihood-based model selection criteria are valid. This
enables us to compare structures under the principle that
similar states may be merged if the consequences of
occupying them are the same. Here, the ‘consequences’ for
a patient consist of the potential exit states, the probabili-
ties of transition to these exit states, the costs and the
utilities. We show that smaller models can be reformulated
into practically equivalent models on the larger state space
by constraining the outward transition probabilities, costs
and utilities to be the same for the ‘merged’ states. The
model choice is then a matter of assessing whether each of
these constraints is reasonable, based on the fit to data. We
also consider using ‘partially merged’ models with differ-
ent state structures for transition probabilities, costs and
utilities, depending on the most appropriate choice for each
consequence; for example, we may assume the costs in
high-risk CAD (cH) to be the same as those in low-risk
CAD (cL) but that the transition probabilities to the dead
state (PHD and PLD) are different. We illustrate our
Low risk CAD 
(L)
High risk CAD 
(H)
CAD (C)Dead (D) Dead (D)
Fig. 1 Coronary artery disease (CAD) models with split and merged CAD severity. PXY is the probability of making a transition from state X to
state Y in a cycle
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approach in models comparing treatment strategies for the
management of depression, and diagnostic tests for CAD.
2 Methods for Comparing State Structures
by Assessing Parameter Constraints
Suppose we have data consisting of the numbers of indi-
viduals who are observed to make a transition between
each pair of states over a particular time interval, and
corresponding denominators of the total number of patients
at risk. The models are fitted to these data by maximum
likelihood or Bayesian estimation, giving estimates of
transition probabilities between states over one cycle of a
discrete-time model [18]. If such data are not explicitly
available, they might be derived from related data (such as
published relative risks of death) under weak assumptions,
and we discuss an example in Sect. 4. Costs and utilities for
states are estimated from samples of individual-level costs
and utilities, or from published unit costs combined with
assumptions, expert beliefs or data on individual resource
use.
2.1 Merging Two States with One Common Exit
State
Consider again the split- and merged-state models for CAD
presented in Fig. 1. It is intuitive that if we impose the
constraint:
PHD ¼ PLD ¼ PD; ð1Þ
the fitted models should give the same predictions of
expected survival. We prove this formally in Appendix 1 in
ESM by showing that the likelihood of the split-state
model, subject to the above constraint, is proportional to
that of the merged-state model, with a proportionality
factor that is independent of PD. Thus, the estimate of PD,
and thus the expected survival over any time horizon, will
be identical under both the constrained split- and merged-
state models. This also applies to Bayesian estimation if the
prior on PD is the same in the merged and constrained
models, and to ‘reversible’ models where the transition
back from high to low is permitted because the probability
of death PDwould remain independent of the disease state.
Furthermore, if we also constrain the costs and utilities of
the states to be equal, as cH ¼ cL ¼ c and uH ¼ uL ¼ u, the
models will give the same predictions of lifetime costs and
quality-adjusted survival, and hence the same decision
recommendations.
Thus, the uncertainty regarding state structure has been
parameterised, as a choice of whether these three constraints
are reasonable. If all three are supported by the data, the
merged model can be used because it is equivalent to the
constrained split model. If all constraints are invalid, then the
fully split model is most appropriate. A ‘partially merged’
model can also be recommended, for example, if the transition
probabilities but not the costs are found to be equivalent.
2.2 Merging Any Number of States with Any
Number of Exit States
The principle and procedure outlined above apply to models
in which the states to be merged have any number of ‘exit
states’, for example, different causes of death, provided the
exit states are common to the states to be merged. Figure 2
illustrates two models; one splits states A and B while the
second merges these states. The exit states, E1; . . .;Em, are
the same for states A and B. To make the split-state model
equivalent to the merged state-model, we use the constraints
PAEi ¼ PBEi ;
for i ¼ 1; . . .;m, where PAEi and PBEi are the probability of
transiting to state Ei from A and B, respectively, and
constrain the costs and utilities as before, cA ¼ cB ¼ c and
uA ¼ uB ¼ u. Thus, the model choice involves determin-
ing, for each i, whether the probability of death from cause
i, the cost and the utility depends on the disease status
being A or B.
A further generalisation is illustrated in Fig. 3. In this
case, we consider merging n states A1; . . .;An with transi-
tions to m states E1; . . .;Em. The necessary constraints are
PA1Ei ¼ PA2Ei ¼    ¼ PAnEi ; ð2Þ
for i ¼ 1; . . .;m, and again cAj ¼ c and uAj ¼ u; for j ¼
1; . . .; n: The model can be fully reversible and any tran-
sitions can be allowed between the merging states Aj. The
A B A or B
VS
Fig. 2 Merging states with any number of exit states. States A and B are the states under consideration for merging while Ei is a set of arbitrary
exit states
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constrained likelihood of the split-state model is propor-
tional to that of the merged-state model, as proven formally
in Appendix 2 in ESM.
The states Aj may represent severities of disease, and the
Ei different causes of death, but this result is entirely
general to problems of whether to split or combine a set of
states A1; . . .;An for which the potential destination states
after leaving the set are the same for each i ¼ 1; . . .; n. The
‘split’ and ‘merged’ models shown in Fig. 3 may both be
part of a common larger state structure, for example, there
may also be transitions into the Aj, or into and out of the Ei.
However, only the constraints (2) on the outward transition
probabilities, costs and utilities are required to effectively
‘merge’ the states. Thus, the choice of structures is
parameterised as a choice of whether the outward transition
probabilities, costs and utilities are common between
A1; . . .;An.
2.3 Merging States with Different Exit Transitions
An adaptation is required when the states being merged
have different exit states, as illustrated by models (a) and
(b) in Fig. 4. This is a special case of the structure in Fig. 1,
where we know that the probabilities of death are different
(P13 ¼ 0 and P23 6¼ 0) between the states being considered
for merging. In discrete time, there is no choice of
parameters for which model (a) is equivalent to (b) as a
patient in state 2 may exit directly to state 3, but even with
P12 ¼ 1, a patient starting in state 1 would take at least two
cycles to reach state 3.
However, we can extend model (a) by including a non-
zero transition between states 1 and 3 (P13 6¼ 0) to obtain
model (c) in Fig. 4. This model can be constrained to
model (a) by setting P13 ¼ 0 or to model (b) by setting
P13 ¼ P23. A comparison between models (a) and (b) is
then possible by assessing these constraints on model (c).
3 Application to a Markov Model with Individual
Patient Data: PANDA
In this section, we present an application to a health eco-
nomic model for patients with symptoms of depression for
whom their general practitioner is considering prescribing
anti-depressant medication. The model was used to com-
pare the cost effectiveness of severity thresholds above
which to treat patients with depression with anti-depressant
medication, and to estimate the value of a proposed ran-
domised controlled trial to compare severity thresholds.
The severity of symptoms was measured on the Hamilton
Depression Rating (HAMD) scale, and three alternative
treatment thresholds (HAMD[ 2, HAMD[ 15 or
HAMD[ 25) are compared with a policy of no treatment.
3.1 Model for Cost Effectiveness of Anti-Depressant
Treatment by Depression Severity
The model consists of a short- and a long-term component.
The short-term model uses linear regression based on
published studies [19–21] to predict a patient’s HAMD
score over the first 12 weeks after treatment initiation. The
long-term component is a discrete-time Markov multi-state
model with a 12-week cycle length and a time horizon of
96 weeks (eight cycles). Patients move between four states
of severity: well 0–7 HAMD, mild 8–13 HAMD, moderate
14–18 HAMD and severe/very severe 19–30 HAMD.
These are standard categories defined by the American
or…or 
VS
Fig. 3 Merging any number of states with any number of exit transitions. States Aj are the states under consideration for merging and Ei is a set
of arbitrary exit states
1 2 3
VS
1 / 2 3
1 2 3
Must extend model (a)
(a)
(b)
(c)
Fig. 4 Comparison of two models (a) and (b) where the states to be
merged (1 and 2) have different exit states. These can be compared by
comparing constrained versions of the model (c), an extended version
of model (a). PXY is the probability of making a transition from state
X to state Y in a cycle
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Psychiatric Association [22]. This four-state model is
illustrated in Fig. 5. The joint likelihood of the observed
data is the product of the probabilities of making the
transitions we observed, along with terms for the likeli-
hoods of observed costs and health valuations of observed
state occupancies. The transition probabilities are esti-
mated by maximum likelihood from the numbers of indi-
viduals observed to move between each pair of states in
merged data from the control arms of the IPCRESS,
THREshold for AntiDepressant response (THREAD) and
TREAD studies [23–25]. Log-normal distributions were
used for state costs. These depended on dosing and moni-
toring regimes inferred from expert clinical opinion and
publicly available drug and services costs [26, 27]. As
clinical evidence and opinion was that anti-depressant
medications have no effect on transition probabilities
beyond the initial 12-week period [28], we used the same
probabilities between the categories of depression severity
in the treated and untreated components. However, the
distributions of HAMD at 12 weeks will differ between
treated and untreated patients, as will their costs. Owing to
a lack of reliable evidence, state utilities were not modelled
directly. We instead mapped incremental gains in HAMD,
defined as the difference between the mid-points of the
category range, to incremental health utilities using pub-
lished evidence [29–31].
3.2 Alternative Model Structures and Results
The transition probabilities between the four states are
informed only by the individual transition history data, and
there is no prior clinical belief regarding, for example, how
the transition probability to well differs between mild,
moderate and severe. Therefore, it is possible that, for these
data, a more parsimonious structure that merges two or
more of these states could give more precise estimates of
cost effectiveness. Thus, we consider a ‘two-state’ model
merging all depression states, a ‘Mod-Severe’ model
merging the moderate and severe states, and a ‘Mild-Mod’
model merging the mild and moderate states. Merged
IPCRESS, THREAD and TREAD data were re-analysed to
estimate these transition probabilities for each structure.
Costs for merged health states are estimated as weighted
averages of their constituent costs, with weights defined by
the baseline prevalence of the four depression states. The
same prevalence was assumed for each cycle as the
available prevalence estimate was representative of an
average distribution over time. Utilities were mapped from
incremental gains in HAMD. These models with ‘fully
merged’ states ignore any prior clinical belief that costs or
utilities are different between the states (Table 3). Finally,
we consider ‘partially merged’ models, where outward
transition probabilities across states are assumed to be
equal but costs and HAMD, and therefore utilities, asso-
ciated with the states are assumed to be different.
The HAMD[2 threshold was the most cost effective at a
willingness-to-pay threshold of £20,000 for all but the two-
state model, where ‘‘no treatment at any HAMD threshold’’
was most cost effective (Table 1). The lower cycle costs
for mild depression (£110 treated, £49 untreated) than for
depression of any severity in the two-state model (£186
treated, £149 untreated) explain the substantial difference
Well (1) 
Moderate 
(3) Mild (2) Severe (4) 
Well (1) 
Moderate or Severe (3|4) Mild (2) 
Well (1) 
Mild, Moderate or Severe (2|3|4) 
Well (1) 
Mild or Moderate (2|3) Severe (4) 
4-state 2-state 
doM-dliMetats-3ereveS-doMetats-3
Fig. 5 Alternative state structures for the PANDA multi-state depression model. The same structure is assumed for the treated and untreated
component of the longer-term PANDA depression model. PANDA Prescribing ANtiDepressants that will leAd to a clinical benefit study
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in decision recommendation (Table 2). The EVPI results
indicate a short-term trial with a 12-week follow-up is cost
effective under all models, though the absolute EVPI
estimates vary from approximately £70 to £95 million
between the models. A long-term trial, with 2 years of
follow-up to better inform the Markov model components,
is not likely to be cost effective under any of the models
except the two-state model. However, when costs and
utilities differ but the outward transition probabilities are
merged, the decision and research recommendations are the
same across all models (Table 1).
3.3 Comparison of State Structures Using
Constraints
We compare models by constraining parameters in the full
(four-state) model to produce models that are equivalent to
those with two or three states. We label the four health
states as 1 (well), 2 (mild), 3 (moderate) and 4 (severe).
The multi-state models being compared are illustrated in
Fig. 5.
The four-state model is equivalent to the two-state
model if the ‘recovery rates’ are constrained to be inde-
pendent of depression severity, thus P21 ¼ P31 ¼ P41, and
if the costs and HAMD/utilities of the mild, moderate and
severe states are assumed to be equal to those of the single
depressed state in the two-state model. To constrain the
four-state model to be equivalent to the three-state ‘Mod-
Severe’ model, we constrain the recovery rates to ‘well’
and the rates to ‘mild’ to be the same, P31 ¼ P41 and
P32 ¼ P42, respectively, and constrain the costs and
HAMD/utilities of the states to be equal. Likewise, the
four-state model is constrained to the three-state ‘Mild-
Mod’ model by constraining the recovery rates to ‘well’
and the progression rates to ‘severe’, P21 ¼ P31, P24 ¼ P34,
along with the costs and HAMD/utilities for the mild and
moderate states. Other transition probabilities, such as the
probabilities of relapse (P12, P13;P14), are unaffected by
the constraints.
Each constraint is assessed by comparing the likeli-
hood and AIC contributions, describing how well the
resulting model fits when estimated using corresponding
observed transitions between states. Full details of this
method are given in Appendix 3 in ESM. The log-like-
lihood and AIC for each potential constraint are given in
Table 2. An example code to conduct the comparisons in
the R statistical software [32] is presented in Appendix 6
in ESM.
Table 1 Results of cost-effectiveness value of information analyses for PANDA based on possible models for depression
Model Optimal
strategy
INB (£) of optimal strategy at
willingness to pay £20,000a
P(CE) of optimal
strategy at
willingness to pay
£20,000b
EVPI
(£million)
EVPPI short
term (£million)
EVPPI long
term
(£million)
Four-state (full) HAMD[ 2 223 (-217 to 798) 0.64 80.04 67.29 0
Two-statec No
treatment
NA 0.61 95.61 103.62 4.11
Three-state (Mod-
Severe)
HAMD[ 2 224 (-213 to 805) 0.67 74.88 62.26 0
Three-state (Mild-Mod) HAMD[ 2 234 (-205 to 830) 0.68 70.70 60.53 0
Two-state unconstrained
costsd
HAMD[ 2 225 (-214 to 812) 0.65 77.95 65.45 0
Three-state (Mod-
Severe) unconstrained
costs
HAMD[ 2 224 (-212, 813) 0.65 77.41 64.88 0
Three-state (Mild-Mod)
unconstrained costs
HAMD[ 2 228 (-205, 830) 0.65 77.06 64.61 0
CE cost-effective, EVPI expected value of perfect information, EVPPI expected value of partial perfect information, HAMD Hamilton Depression
Rating scale, INB incremental net benefit, Mod-Severe moderate-severe, NA, PANDA Prescribing ANtiDepressants that will leAd to a clinical
benefit study
a Expected INB of treatment if HAMD[ 2 strategy vs. no treatment
b P(CE) is probability of treatment if HAMD[ 2 strategy has highest net benefit
c No treatment was the most CE strategy under the two-state model with P(CE) = 0.61, treat if HAMD[ 25 was second most CE with INB of -
2 (-24, 26) and P(CE) = 0.32, while HAMD[ 2 had an INB of -306 (-757, 289) and P(CE) of 0.01 under the two-state model
d Unconstrained costs models use four states for costs and HAMD/utilities but merged/constrained models for transition probabilities
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Under the unconstrained four-state model, the estimated
recovery rates to well are substantially different for a
patient with severe depression, thus P41 6¼ P31 and
P41 6¼ P21. This is shown formally by the lower AIC for
P21 6¼ P31 6¼ P41 compared with the constraints where
P31 ¼ P41 or P21 ¼ P41. However, the recovery rates are
similar between mild and moderate, thus the AIC is not
changed substantially when moving between P21 ¼ P31
and P21 6¼ P31. The differences between P32 and P42 and
between P24 and P34 under the four-state model are less
striking. This is confirmed by the small difference in AIC
between P32 ¼ P42and P32 6¼ P42, and between P24 ¼ P34
and P24 6¼ P34. Thus, on the basis of transition probabili-
ties, there is a negligible difference between the three-state
Mild-Mod and four-state models, and these are both
preferred over the two- and three-state Mod-Severe mod-
els, as expected.
Second, we compare the costs informally because these
were based on expert belief. The treated costs are the same,
though the untreated costs are slightly different, between
mild and moderate. Thus, there is some evidence that a
model with unconstrained costs is more appropriate. The
costs for severe depression are substantially different from
mild and moderate depression, arguing against the two-
state and ‘Mod-Severe’ models. Prior judgement deemed
that utilities are primarily determined by severity of
depression, which broadly favours models that have finer
classifications of HAMD.
Based on the chosen model, ‘treat if HAMD[ 2’ is the
optimal strategy. Because the model extrapolates beyond
Table 2 Comparison of transition probabilities and costs for the four Markov cost-effectiveness depression models
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HAMD-D scores included in trials, we conclude that anti-
depressant medications are cost effective over the range of
HAMD scores included in the trials. We also conclude that
there is likely to be value in a short-term trial that recruits
patients with milder disease (lower HAMD scores); how-
ever, a long-term follow-up is not likely to be cost
effective.
4 Application to a Model Informed by Published
Parameters: CECaT
In this application, there are no individual-level data.
Instead, the transition probabilities out of the states being
considered for merging are obtained from published esti-
mates. To formally compare the state structures, we have to
derive the implicit transition counts underlying the pub-
lished data.
The Cost-Effectiveness of non-invasive Cardiac Testing
(CECaT) study [33] was a randomised trial of diagnostic
strategies for CAD, comparing angiography alone with
three non-invasive functional tests (followed by
confirmatory angiography if positive). Following the trial,
a Markov multi-state health economic model was devel-
oped, based on previous models by Mowatt et al. [34, 35]
and Kuntz et al. [36]. The full structure and assumptions
are detailed by Thom [17]. Briefly, a patient with suspected
CAD receives one of five alternative diagnostic test
strategies and is assigned a diagnosed severity, as a result
of which they may receive either medical management or
revascularisation. The diagnosed severity may be incorrect
because the tests are not perfect and vary in their sensitivity
and specificity. The model then proceeds with an annual
cycle for 30 years, and at each cycle, a patient may have a
myocardial infarction and/or die from any cause.
In these models, CAD severity is categorised into dis-
crete states, representing the increasing risk of myocardial
infarction and death, and the increasing need for revascu-
larisation. Mowatt et al. [34, 35] used three risk states: low
(no CAD), medium (CAD in one or two vessels excluding
the left main stem) or high (CAD in three or more vessels
and poor left-ventricular function, or disease in the left
main stem). We compare the three-state categorisation with
a model where medium- and high-risk states are merged,
Table 2 continued
For each destination state (well, mild, moderate, severe) the likelihood and AIC are given corresponding to the constraint on the probabilities of
transition into this state implied by each model. Models with lower AIC are preferred. Shaded cells indicate parameters that are constrained to be
equal in each model
AIC Akaike information criterion
P24 is unconstrained in the Mod-Severe model; P42 is unconstrained in the Mild-Mod model
a Values are mean and 95% credible intervals
b Clinical opinion was that costs for mild and moderate treated patients in the four-state model should be the same
c Costs for well patients receiving antidepressants is only the cost of the drug, which is fixed by the British National Formulary list price
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giving two states representing no CAD or CAD. While the
three-state representation is typically used in the literature,
it relies on having sufficient information about the differ-
ences between medium and high risk to justify separating
them. Under the two models, the optimal diagnostic strat-
egy at conventional cost-effectiveness thresholds, and
extent of decision uncertainty, are different [17].
Table 3 shows published data used in the full model.
The risk of death relative to no CAD differs (significantly)
between the two risk groups, but the probability of non-
fatal myocardial infarction, the costs and the utilities are
similar between the medium- and high-risk groups. The
95% confidence intervals for the state-specific relative risks
of death do not overlap, suggesting that they are different
enough to merit separation in the model. For a more formal
comparison, we derive the implicit data from which these
relative risks were obtained: the numbers of people dying
in 1 year, and associated denominators, for medium and
high risk. Appendix 4 in ESM details how this is done. The
problem can then be framed as a comparison of two sta-
tistical models for a pair of binomially distributed obser-
vations (126 deaths out of 571 in medium risk, and 259 out
of 754 in high risk): one model with different probabilities
of death, and one where the death probability is constrained
to be the same, between medium and high risk. These
models have AICs of 17.4 and 39.6, respectively, strongly
favouring separate risk states (Table 3).
A similar analysis is performed for the risk of non-fatal
myocardial infarction, which has overlapping confidence
intervals between medium and high risk, though this does
not necessarily imply a non-significant difference. An AIC
difference of -0.6, however, mildly favours a common risk
between the ‘medium’ and ‘high’ states.
The costs and utilities used for the medium- and high-risk
states in the economic model (excluding the costs of
revascularisation) were estimated from the subset of patients
in the CECaT trial whose CAD severity was known. With
only 19 of these patients in high risk and 59 in medium risk,
it is not clear from the data in Table 3 whether we can
assume that expected cost and utility are different between
medium and high risk. To assess this formally, generalised
linear regression models were fitted to the individual-level
cost and utility outcomes by maximum likelihood in R [32],
using a gamma distribution for the costs, and a truncated
normal distribution for the utilities. The AIC marginally
favours a model with different mean costs (AIC difference
1.4) and a model with common mean utility (AIC difference
-1.4) between medium and high risk.
Thus, in this model, separating medium- and high-risk
states is strongly justified based on their different mortality
rates. Though within this structure, there is some evidence
that constraining the myocardial infarction rates and utilities
to be common between the states will lead to a better trade-
off between model fit and model complexity, or bias and
precision. Appendix 7 in ESM provides an example R code
for all the likelihood and AIC calculations in this example.
5 Discussion
Currently, state structure choices are made informally,
based upon clinical opinion or availability of data, or
compared through simple scenario analyses [2, 7–9]. In this
article, we have developed a formal statistical basis to
compare state structures in cost-effectiveness models.
Specifically, two or more similar states in a transition
model can be merged if they have the same consequences
for a patient who enters them. The models are then com-
pared by assessing a constraint on these consequences
using standard statistical methods, if the parameters are
Table 3 Published and derived data on parameters of the CECaT model of coronary artery disease, and AIC difference assessing the constraint
that the corresponding parameters are equal between medium- and high-risk states (positive AIC difference favours different parameters)
Medium risk High risk AIC (medium = high)
- AIC (medium = high)
Published parameter estimates (with 95% CI)
Relative risk of death (vs. no CAD) 2.3 (1.9–2.8) 3.6 (3.1–4.1)
Annual risk of non-fatal MI 0.022 (0.016–0.029) 0.028 (0.021–0.035)
Derived event count data
Number/denominator of deaths in 1 year (%) 126/571 (22) 259/754 (34) 22.2
Number/denominator of non-fatal MIs (%) 39/1717 (2.2) 62/2159 (2.8) -0.6
Summary of individual-level data (mean, SD, sample size)
Costs 1530, 880, n = 59 1930, 1070, n = 19 1.4
Utilities 0.81, 0.12, n = 59 0.78, 0.21, n = 19 -1.4
AIC Akaike information criterion, CAD coronary artery disease, CI confidence interval, CECaT Cost Effectiveness of non-invasive Cardiac
Testing, MI myocardial infarction, SD standard deviation
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estimated from data, or by expert belief. Thus, we can
decide whether the risk of bias in a more parsimonious
model outweighs the reduced uncertainty from such a
model. While assessing constraints on parameters is com-
mon practice, we have shown that models with merged
states and models with constrained parameters can be used
interchangeably. We proved that this method works for
comparing any pair of structures where the states to be
merged have the same exit states (Sect. 2.2) and that the
method can be adapted to work if they have different exit
states (Sect. 2.3). We also showed this method to be
valuable even if state structure uncertainties do not affect
the current treatment decision as the value of further
research, quantified by the EVPI, expected value of partial
perfect information or the expected value of sample
information, may be sensitive to structural choices [14].
Statistical methods to assess the equality of model
parameters require that the data used to estimate those
parameters are available, to form the likelihood. For transition
probabilities, the number of individuals who are observed to
move between each pair of states in a time period, and
denominators are required. The Prescribing ANtiDepressants
that will leAd to a clinical benefit (PANDA) study used ran-
domised controlled trials but our methods apply to any source,
including registries or cohort studies, which provide the data
necessary to estimate transition probabilities. We recommend
using the data to choose the appropriate state structure before
building the full model. Individual patient data were not
available for the CECaT model. W recreated the numerators
and denominators by assuming that the split between risk
groups was the same across randomised arms of the trial,
which should approximately hold if randomisation was ade-
quate. To aid such calculations, we recommend that data of
this form are published routinely.
Constraints for state selection can also be applied to
continuous time multi-state models, which have been
advocated for use in health economic modelling [37, 38],
as we show in Appendix 5 in ESM, and to the selection of
structures for patient-level simulation and heterogeneity
models through the inclusion of covariates on the transition
probabilities and comparing their effects between states.
The principle should also extend to non-Markov multi-state
models but this needs to be investigated. In a Bayesian
model comparison, expert belief can be used by placing
prior probabilities on parameters or model structures and
combining with data via Bayes theorem.
Conversely, our method deals only with comparing multi-
state structures. Further research into formal statistical
methods for other forms of structural uncertainty is required.
The choice between continuous and discrete outcome
models is difficult. A multi-state model for changes in dis-
ease severity is essentially a continuous outcome model,
where ranges of the outcome are constrained to have
equivalent costs, utilities and future disease progression.
However, there is no routinely applicable method to con-
strain a multi-level regression model, for example, to be
equivalent to a multi-state model. Consideration is also
required for more complex models, such as dynamic trans-
mission models in infectious diseases [6, 39].
6 Conclusion
We have developed a formal method to parameterise state
structure uncertainty using constraints on the parameters of
the most complex model and have illustrated its wide
applicability through examples in depression and CAD.
Further research is required for structural uncertainty in
non-multi-state cost-effectiveness models.
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